Publications &
Posters

Abstract Background: Efforts to identify accurate blood biomarkers for neurodegenerative disease hallmarks have been hampered by the lack of a proteomic tool that has the required sensitivity to detect very low concentrations of brain-derived proteins in plasma or serum and the ability to multiplex many analytes in a single assay.

Abstract Background: Efforts to identify accurate blood biomarkers for neurodegenerative disease hallmarks have been hampered by the lack of a proteomic tool that has the required sensitivity to detect very low concentrations of brain-derived proteins in plasma or serum and the ability to multiplex many analytes in a single assay.

Cytokines and chemokines are critical components of the immune system and play important roles in autoimmune diseases. Comprehensive profiling of proteins in blood can provide deeper insights into the mechanisms underlying this highly complex and heterogeneous group of diseases. However, many of these proteins are present at very low concentrations

Neurodegenerative disease markers like neurofilament light protein (NFL) and phosphorylated Tau 181 (p-Tau) can be detected in cerebrospinal fluid (CSF) and are already being used in diagnosis and to guide therapeutic development. However, broad adoption of these tests is hindered by the invasive nature and high cost of CSF sampling.